Cytotoxic T lymphocyte-associated antigen 4 in acute rejection after renal transplantation

doi:10.3969/j.issn.2095-4344.2014.05.013

Abstract

Abstract:

BACKGROUND: Cytotoxic T lymphocyte-associated antigen 4 is a newly discovered costimulatory molecule. It has been studied more in tumor and autoimmune diseases, less in the field of kidney transplantation.

OBJECTIVE: To explore the role of cytotoxic T lymphocyte-associated antigen 4 in acute rejection after renal transplantation.

METHODS: Fifty patients undergoing renal transplantation were divided into acute rejection group (20 cases) and stable graft function group (30 cases). Another 30 healthy persons served as control group. Blood samples were extracted from the peripheral blood. Cytotoxic T lymphocyte-associated antigen 4 was detected by enzyme linked immunosorbent assay and flow cytometry.

RESULTS AND CONCLUSION: The expression of cytotoxic T lymphocyte-associated antigen 4 in the serum showed significant differences in the acute rejection group, stable graft function group and healthy control group (F=70.008 1, P=0.000 0), but showed no difference in peripheral blood lymphocytes of three groups (F=1.865 6, P=0.161 7). Compared with the healthy control group, the expression levels of cytotoxic T lymphocyte-associated antigen 4 in peripheral blood lymphocytes of acute rejection group and stable graft function group were significantly decreased (P=0.000 0). In addition, the acute rejection group had a lower cytotoxic T lymphocyte-associated antigen 4 expression than the stable graft function group (P=0.000 0). In renal transplant rejection, the expression of cytotoxic T lymphocyte-associated antigen 4 in serum was reduced, showing some correlation with acute rejection after renal transplnatation. Cytotoxic T lymphocyte-associated antigen 4 might be involved in the rejection.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: transplantation, kidney transplantation, graft rejection, uremia, immunosuppressive agents, flow cytometry

CLC Number:

R318

Chen Chang-qing, Shi Bing-yi, Cai Ming, Zhao Yu-bo, Jin Bo-quan, Wang Chun-yan, Han Yong, Xiao Li, Zhou Wen-qiang, Li Zhou-li. Cytotoxic T lymphocyte-associated antigen 4 in acute rejection after renal transplantation[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(5): 730-735.

Figures/Tables 3

References

[1] Moreso F, Hernández D.Has the survival of the graft improved after renal transplantation in the era of modern immunosuppression? Nefrologia. 2013;33(1):14-26

[2] 陈江华,韩飞.移植肾急性排斥反应新认识[J].中华移植杂志: 电子版,2010,4(3):41-44.

[3] Wadia PP, Tambur AR. Yin and Yan of cytokine regulation in solid organ graft rejection and tolerance. Clin Lab Med. 2008; 28(3):469-479.

[4] Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med. 2008;14(1): 88-92.

[5] Li J, Lai X, Liao W, et al. The dynamic changes of Th17/Treg cytokines in rat liver transplant rejection and tolerance. Int Immunopharmacol.2011;11(8): 962-967.

[6] 刘文宇,张雷,朱有华.T淋巴细胞在肾移植排斥反应中的作用[J]. 中华器官移植杂志,2011,32(12):765-767.

[7] 彭勇,龚建平.共刺激分子与移植免疫耐受[J].中国普外基础与临床杂志,2010,17(6):552-556.

[8] Graca L, Honey K, Adams E, et al. Cutting edge:anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol. 2000;165(9): 4783-4786.

[9] Shimizu K, Schnbeck U, Mach F, et al. Host CD40 ligand deficiency induces long-term allograft survival and donor-special tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol. 2000; 165(6):3506-3518.

[10] Liu SM, Sutherland AP, Zhang Z, et al.Overexpression of the CTLA-4 isoform lacking exons 2 and 3 causes autoimmunity. Immunol.2012;188(1):155-162.

[11] Walunas TL, Lenschow DJ, Bakker CY, et al.CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-413.

[12] Tosti G, Cocorocchio E, Pennacchioli E.Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol. 2013;6:245-256.

[13] Antczak A, Pastuszak-Lewandoska D, Górski P,et al.Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer. Biomed Res Int. 2013; 2013:576486.

[14] Lesterhuis WJ, Salmons J, Nowak AK,et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One. 2013;8(4): e61895.

[15] Kow NY, Mak A. Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus. Clin Dev Immunol. 2013;2013:245928.

[16] Stumpf M, Zhou X, Bluestone JA. The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol. 2013;190(3):961-969.

[17] Watanabe N, Nakajima H.Coinhibitory molecules in autoimmune diseases. Clin Dev Immunol. 2012;2012:269756.

[18] Pieper J, Herrath J, Raghavan S,et al. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14:34.

[19] Ruocco MG, Pilones KA, Kawashima N, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. Clin Invest. 2012;122(10): 3718-3730.

[20] Lin H, Rathmell JC, Gray GS, et al. Cytotoxic T lymphocyte antigen 4(CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.J Exp Med. 1998;188(1):199-204.

[21] Zhou P, Szot GL, Guo Z, et al. Roles of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol. 2000;165 (10):5580-5587.

[22] Kwek SS, Dao V, Roy R,et al. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer atients. Immunol. 2012;189(7):3759-3766.

[23] Kroczek R, Hamelmann E. T cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies. J Allegry Clin Immunol. 2005; 116(4):906-909.

[24] Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013;13: 5.

[25] Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Ann Rev Immunol. 2006;24:65-97.

[26] Walunus TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(15):405-413.

[27] Auchincloss H, Turka LA. CTLA-4: not all costimulation is stimulatory. J Immunol. 2011;187: 3457-3458.

[28] 蔡雷,于善谦,朱乃硕.抗人CTLA-4单克隆抗体的制备及其生物学活性研究[J].上海免疫学杂志,2002,22(3):168-172.

[29] Krummel MF, Allison JP.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459-465.

[30] McGrath MM, Najafian N.The role of coinhibitory signaling pathways in transplantation and tolerance. Front Immunol. 2012;3:47.

[31] Brunet JF, Denizot F, Luciani MF,et al. A new member of the immunoglobulin super- family--CTLA-4. Nature. 1987;328 (6127):267-270.

[32] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-1570.

[33] Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev. 2009;229:67-87.

[34] Yokosuka T, Kobayashi W, Takamatsu M, et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity. 2010;33:326-339.

[35] Liu MF, Wang CR, Chen PC, et al. Increased expression of soluble cytotoxic T-lymphocyte -associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J Immunol. 2003;57(6): 568-572.

[36] Tsai MK, Ho HN, Chien HF, et al. The role of B7 ligands (CD80 and CD86) in CD152-mediated allograft tolerance: a crosscheck hypothesis. Transplantation. 2004;77:48-54.

[37] Wang X, Hao J, Metzger DL,et al. Blockade of both B7-H4 and CTLA-4 co-signaling pathways enhances mouse islet allograft survival. Islets. 2012;4(4):284-295.

[38] Li J, Zhu H, Wang S, et al. Blockade of NKG2D synergized with CTLA4-Ig in promoting long-term graft survival in murine models of cardiac transplantation. Transplantation. 2012; 93(4):356-363.

[39] Minguela A, Marín L, Torío A, et al. CD28/CTLA-4 and CD80/CD86 costimulatory molecules are mainly involved in acceptance or rejection of human liver transplant. Hum Immunol. 2000;61(7): 658-669.

[40] Demirkiran A, Kok A, Kwekkeboom J, et al. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl. 2006;12(2): 277-284.